Safety of in-hospital insertable cardiac monitor procedures performed outside the traditional settings: results from the Reveal LINQ in-office 2 international study.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
31 05 2019
Historique:
received: 19 08 2018
accepted: 17 05 2019
entrez: 2 6 2019
pubmed: 4 6 2019
medline: 19 3 2020
Statut: epublish

Résumé

Historically, the majority of insertable cardiac monitor (ICM) procedures were performed in the cardiac catheterization (cath) lab, electrophysiology (EP) lab, or operating room (OR). The miniaturization of ICMs allows the procedure to be relocated within the hospital without compromising patient safety. We sought to estimate the rate of untoward events associated with procedures performed within the hospital but outside the traditional settings and to characterize resource utilization, procedure time intervals, and physician experience. The Reveal LINQ in-Office 2 (RIO 2) International study was a single arm, multicenter, prospective study. Patients indicated for an ICM and willing to undergo device insertion outside the cath/EP lab or OR were eligible and followed for 90 days after insertion. A total of 191 patients (45.5% female aged 63.8 ± 26.9 years) underwent successful Reveal LINQ ICM insertion at 17 centers in Europe, Canada and Australia. The median total visit duration was 106 min (interquartile range [IQR]: 55-61). Patient preparation and patient education accounted for 10 min (IQR: 5-20) and 10 min (IQR: 8-15) of total visit duration, respectively. Preparation and education occurred in the procedure room for 90.6 and 60.2% of patients, respectively. There were no untoward events (0.0, 95% CI: 0.0-2.1%) though four patients presented with procedure-related adverse events that did not require invasive intervention. Physicians rated procedure location as convenient or very convenient. The Reveal LINQ™ ICM insertion can be safely and efficiently performed in the hospital outside the cath/EP lab or OR. ClinicalTrials.gov identifier NCT02412488 ; registered on April 9, 2015.

Sections du résumé

BACKGROUND
Historically, the majority of insertable cardiac monitor (ICM) procedures were performed in the cardiac catheterization (cath) lab, electrophysiology (EP) lab, or operating room (OR). The miniaturization of ICMs allows the procedure to be relocated within the hospital without compromising patient safety. We sought to estimate the rate of untoward events associated with procedures performed within the hospital but outside the traditional settings and to characterize resource utilization, procedure time intervals, and physician experience.
METHODS
The Reveal LINQ in-Office 2 (RIO 2) International study was a single arm, multicenter, prospective study. Patients indicated for an ICM and willing to undergo device insertion outside the cath/EP lab or OR were eligible and followed for 90 days after insertion.
RESULTS
A total of 191 patients (45.5% female aged 63.8 ± 26.9 years) underwent successful Reveal LINQ ICM insertion at 17 centers in Europe, Canada and Australia. The median total visit duration was 106 min (interquartile range [IQR]: 55-61). Patient preparation and patient education accounted for 10 min (IQR: 5-20) and 10 min (IQR: 8-15) of total visit duration, respectively. Preparation and education occurred in the procedure room for 90.6 and 60.2% of patients, respectively. There were no untoward events (0.0, 95% CI: 0.0-2.1%) though four patients presented with procedure-related adverse events that did not require invasive intervention. Physicians rated procedure location as convenient or very convenient.
CONCLUSIONS
The Reveal LINQ™ ICM insertion can be safely and efficiently performed in the hospital outside the cath/EP lab or OR.
TRIAL REGISTRATION
ClinicalTrials.gov identifier NCT02412488 ; registered on April 9, 2015.

Identifiants

pubmed: 31151383
doi: 10.1186/s12872-019-1106-3
pii: 10.1186/s12872-019-1106-3
pmc: PMC6545016
doi:

Banques de données

ClinicalTrials.gov
['NCT02412488']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

132

Références

Europace. 2018 Jun 1;20(6):1050-1057
pubmed: 29016753
J Cardiovasc Med (Hagerstown). 2017 Jul;18(7):550-552
pubmed: 27322402
Heart Rhythm. 2017 Feb;14(2):218-224
pubmed: 27825975
Int J Cardiol. 2016 Nov 15;223:13-17
pubmed: 27525370
Expert Rev Med Devices. 2015 Jan;12(1):7-18
pubmed: 25154970
Indian Pacing Electrophysiol J. 2017 Nov - Dec;17(6):163-166
pubmed: 29231819
Europace. 2016 Jun;18(6):919-24
pubmed: 26293624
Am Heart J. 2019 Jan;207:76-82
pubmed: 30487072
Pacing Clin Electrophysiol. 2017 Sep;40(9):982-985
pubmed: 28691385
Pacing Clin Electrophysiol. 2015 Dec;38(12):1464-9
pubmed: 26412309
Int J Cardiol. 2017 Aug 15;241:229-234
pubmed: 28457562

Auteurs

Prashanthan Sanders (P)

Department of Cardiology, Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, SA, 5000, Australia. prash.sanders@adelaide.edu.au.

Christopher Piorkowski (C)

Herzzentrum Dresden- Abteilung für Invasive Elektrophysiologie, Dresden, Germany.

Johannes A Kragten (JA)

Zuyderland Medisch Centrum Heerlen, Heerlen, Netherlands.

Grahame K Goode (GK)

Blackpool, Fylde and Wyre Hospitals, NHS Foundation, Blackpool, UK.

Satish R Raj (SR)

Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada.

Trang Dinh (T)

Maastricht University Medical Center, Maastricht, Netherlands.

M Rizwan Sohail (MR)

Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Rishi Anand (R)

Holy Cross Hospital, Fort Lauderdale, FL, USA.

Angel Moya-Mitjans (A)

Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Noreli Franco (N)

Cardiac Rhythm and Heart Failure, Medtronic, Inc, Mounds View, MN, USA.

Kurt Stromberg (K)

Cardiac Rhythm and Heart Failure, Medtronic, Inc, Mounds View, MN, USA.

John D Rogers (JD)

Scripps Prebys Cardiovascular Institute, La Jolla, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH